Vestronidase alfa

(Mepsevii)

Vestronidase alfa

Drug updated on 12/19/2023

Dosage FormInjection (intravenous: 10 mg/5 mL)
Drug ClassRecombinant human lysosomal beta glucuronidases
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of Mucopolysaccharidosis VII (MPS VII, Sly syndrome) in pediatric and adult patients.

Product Monograph / Prescribing Information

Document TitleYearSource
Mepsevii (vestronidase alfa) Prescribing Information.2020Ultragenyx Pharmaceutical Inc, Novato, CA

Randomized Controlled Trials

Document TitleSex DistributionYearSource
The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII.
12Subjects
F: 67%
M: 33%
2020Molecular genetics and metabolism

Sex Distribution:

F:67%
M:33%
12Subjects

Year:

2020

Source:Molecular genetics and metabolism